Sensus Healthcare Inc (SRTS)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$3.19-2.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · SRTS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on accelerating customer adoption, expanding commercial reach, and growing the sales pipeline across domestic and international markets.
Stated as a priority in 2 of last 2 quarters. Revenue declined from $3.4M in 2026-Q1 to $2.3M in 2026-Q2, partly due to timing of financing approvals and no sales to a historically large customer. Management reports accelerating customer adoption and pipeline expansion domestically and internationally, indicating commercial momentum despite revenue timing effects.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Customer adoption accelerated through expanding engagement with independent practices, larger physician groups, and health systems.”
“We are seeing the benefits of the dedicated CPT Codes move from concept to commercial reality, supporting continued diversification of our customer base.”
Grow recurring revenue streams by increasing treatment volumes and placements under the Fair Deal Agreement program.
Stated in 2 of last 2 quarters. Management highlights an 8% increase in treatment volumes under the Fair Deal Agreement program compared to 2025-Q1 and reports increased utilization in 2026-Q2. While revenue recognition timing affects reported sales, the program's expansion supports growth in recurring revenue streams.
“We broadened relationships and increased utilization under our Fair Deal Agreement program.”
“Continued expansion of the Fair Deal Agreement program, with treatment volumes increasing 8% over the first quarter of 2025.”
Utilize new CPT codes effective January 2026 to enhance reimbursement certainty and drive increased customer engagement and sales.
Stated in 2 of last 2 quarters. Management reports that dedicated CPT codes effective January 2026 have increased physician engagement and strengthened the sales pipeline. Despite revenue declines due to timing and customer mix, the regulatory change is supporting commercial activity and reimbursement clarity.
“Sales pipeline strengthened following CPT code implementation, supported by increasing physician education and inbound inquiries.”
“Dedicated CPT Codes for SRT and IG-SRT, effective January 1, 2026, provide reimbursement certainty and increased inquiry levels.”
Focus on advancing the company toward profitability through operational improvements and commercial growth.
Stated in 2 of last 2 quarters. Net loss widened from $2.6M in 2026-Q1 to $8.7M in 2026-Q2, partly due to timing of revenue recognition and increased tax valuation allowance. Adjusted EBITDA improved slightly from negative $4.2M to negative $3.0M. Management reiterates focus on driving toward profitability, but financial results show mixed progress.
“Focused on executing against our five strategic priorities including driving Sensus toward profitability.”
“We are focused on five priorities for 2026: education, adoption, recurring revenue, commercial reach, and driving toward profitability.”
Preserve financial flexibility by utilizing a revolving credit facility to support operations and growth initiatives.
Newly stated in 2026-Q2. The company established a $15 million revolving credit facility in June 2026 to maintain capital flexibility. As of 2026-Q2, there were no outstanding borrowings under this facility, supporting liquidity and operational needs.
“Entered into a $15 million revolving credit facility with City National Bank of Florida.”
Over the trailing year it converted -9.26x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
5 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.